Programs and results
What we aim to solve
Right now, one man dies every 16 minutes from prostate cancer in the United States. PCF’s vision is to end all deaths from prostate cancer by raising awareness and funding urgent, cutting-edge research.
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Young Investigators
PCF created the Young Investigator Awards program with one goal: to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas.
The Young Investigator Awards offer career and project support for young (generally 35 and younger) proven investigators in postdoctoral fellowships or who have recently achieved junior faculty positions and are committing their lives to the field of prostate cancer.
Challenge Awards
One of PCF’s goals is to support transformational prostate cancer research to accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer. How do we hope to accomplish this? By funding cross-disciplinary teams of investigators in strategic areas through our Challenge Awards.
Recognition Awards
PCF and its partners grant awards that recognize top presentations at international cancer research meetings. Recognition Awards go to investigators not currently funded by PCF who have a record of outstanding accomplishments in prostate cancer research.
Where we work
External reviews

Our Sustainable Development Goals
Learn more about Sustainable Development Goals.
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
PCF’s mission is to cure prostate cancer once and for all. Since 1993,
PCF has raised more than $840 million in support of cutting-edge
research by more than 2,200 research projects at 220 leading cancer
centers. Thanks in part to PCF’s commitment to ending death and
suffering from prostate cancer, the death rate is down 52%.
What are the organization's key strategies for making this happen?
*Help researchers learn why 1 in 9 men get prostate cancer—and why it is more deadly to some than others
*Help support scientists who are trying to speed new treatments to patients
*Help connect families and clinicians to the latest standard-of-care information
What are the organization's capabilities for doing this?
PCF continues to fund the most promising research, while increasing the overall distribution of education materials to patients and clinicians.
Thanks in large part to research funded by PCF, new investigational treatments are available for over half of men with metastatic prostate cancer. PARP inhibitors, checkpoint immunotherapy, and PSMA-targeted radionuclide therapy are just three of the strategies on the horizon for men with advanced disease.
What have they accomplished so far and what's next?
In the past 27 years since PCF was founded, deaths from prostate cancer have dropped by 52% and countless more men are alive today as a result. In addition, PCF has made the following accomplishments:
*In the last decade (2010-2020), 11 new drugs were approved for prostate cancer; 10 of those had PCF involvement
*PCF-funded research includes more than 40 different additional therapies currently under investigation
*More than 100,000 patient resources were distributed in 2019 to prostate cancer patients and family members, including: Prostate Cancer Patient Guide; Science of Living Well, Beyond Cancer; Additional Facts for African American Men and Their Families
*PCF-funded research has helped bring 12 precision anti-prostate cancer medicines to market as well as funded countless studies to help identify which patients might benefit from which treatments
At PCF, we will continue fighting prostate cancer without reservation. Our mission is to ensure that families have more days together and — as with every challenge we rip through at PCF — science will prevail in these trying times.
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Prostate Cancer Foundation
Board of directorsas of 02/25/2021
Mike Milken
Prostate Cancer Foundation
Mike Milken
Prostate Cancer Foundation
Charles F. Baird
North Castle Partners
James Blair
Domain Associates
Steven A. Burd
Safeway Inc.
David Ederer
Ederer Investment Company
David J. Epstein
ACS Clearinghouse
R. Christian B. Evensen
Flintridge Capital Investment, LLC
Peter T. Grauer
Bloomberg, L.P
Rosey Grier
Milken Family Foundation
Stuart Holden
Louis Warschaw Prostate Cancer Center, Cedars-Sinai Medical Center, Prostate Cancer Foundation
Arthur Kern
No Affiliation
David Koch
Koch Industries
Earle I. Mack
The Mack Company
Jeffrey A. Marcus
Crestview Advisors
Shmuel Meitar
Aurec Group
Leslie D. Michelson
Private Health Management
Lori Milken
Prostate Cancer Foundation
Jerry Monkarsh
EJM Development
Henry L. Nordhoff
Gen-Probe Incorporated
Lynda Resnick
Roll International
Bert Roberts
No Affiliation
Richard Sandler
Maron & Sandler, The Milken Family Foundation
J. Gary Shansby
Partida Tequila, LLC
Stanley Zax
Zenith National Insurance Corp.
Organizational demographics
Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.
Leadership
No data
Race & ethnicity
No data
Gender identity
No data
No data
Sexual orientation
No data
Disability
No data